Turbine – a London-based company with a cell simulation platform that can predict the effectiveness of cancer treatments – has completed a €20m Series A financing round. Mercia and MSD Global Health Innovation (GHI) Fund (MSD is the trade name of Merck & Co., Inc., Rahway NJ, USA) co-led the financing, joined by .